METABRE - MOLECULAR MECHANISMS INVOLVED IN ORGAN-SPECIFIC METASTATIC GROWTH PROCESSES IN BREAST CANCER (FP6-LIFESCIHEALTH) (2004-01-01 - 2006-12-31) (»add to infobox)

Anna Maria TETI, Roberto BUCCIONE, Rosette LIDEREAU, Philippe CLEZARDIN, Philippe Roger CLEMENT-LACROIX, Gabri VAN DER PLUIJM, Ben-Tsion WILLIGER, Maciej UGORSKI, Suzanne Amy ECCLES, Sierra ANGELS, Marc BRACKE, Vincent CASTRONOVO

UNIVERSITA DEGLI STUDI DELL'AQUILA (ITF11 - L'Aquila) (Italy), CONSORZIO MARIO NEGRI SUD (ITF14 - Chieti) (Italy), CENTRE RENE HUGUENIN (FR105 - Hauts-de-Seine) (France), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR716 - Rhône) (France), PROSKELIA SAS (FR106 - Seine-Saint-Denis) (France), AKADEMISCH ZIEKENHUIS LEIDEN - LEIDEN UNIVERSITAIR MEDISCH CENTRUM (NL331 - Agglomeratie Leiden en Bollenstreek) (Netherlands), CANCERTEK PHARMACEUTICALS LTD (NoRegion - NoRegion) (Israel), AKADEMIA ROLNICZA WE WROCLAWIU THE AGRICULTURAL UNIVERSITY OF WROCLAW (PL514 - Miasto Wroclaw) (Poland), INSTITUTE OF CANCER RESEARCH - ROYAL CANCER HOSPITAL (UKI11 - Inner London - West) (Great Britain), INSTITUT DE RECERCA ONCOLOGICA (ES511 - Barcelona) (Spain), UNIVERSITEIT GENT (BE234 - Arr. Gent) (Belgium), UNIVERSITE DE LIEGE (BE332 - Arr. Liège) (Belgium)

Breast cancers are prone to metastasise, particularly to the lymphatics, bone, liver, lungs and central nervous system tissues. Once solid secondary tumours are established, the chances of long-term survival fall from over 90% to around 5%. The proposed STREP project "METABRE" will investigate the molecular mechanisms of breast cancer metastasis, including the identification and functional analysis of new genes and proteins that characterise the organ-specific metastatic phenotype in breast cancer cells, and the interaction of cancer cells with the affected organ tissues. METABRE will then develop new pharmacological therapies to prevent or treat metastases, and new diagnostic techniques, based on the identification and characterisation of molecular targets implicated in breast cancer metastasis. The project workplan has eleven workpackages for gene profiling and proteomic analysis of tissue samples, functional analysis of newly identified genes and proteins, mechanisms of angiogenesis and invasion, organ-cancer cell interactions, development of pharmacological therapies, development of diagnostic techniques, and preliminary clinical trials of the diagnostic techniques and one of the therapies under development. The consortium has 12 partners from 8 countries and includes leading academic groups in the metastasis field and 2 pharmaceutical companies. The project achieves the necessary critical mass in terms of personnel, scientific expertise, experimental models and finance in order to meet the objectives.

PERSONS (12/12)

RELATED NAVIGATION AREA(S) (5/5)